- SPRO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
Spero Therapeutics (SPRO) S-8Registration of securities for employees
Filed: 15 Mar 24, 4:18pm
Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Spero Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Unit(2) | Maximum Offering | Fee Rate | Amount of Registration Fee | |||||||
Equity | Common Stock, par value $0.001 per share | 457(c) and 457(h) | 500,000 | $1.70505 | $852,525.00 | $0.00014760 | $125.84 | |||||||
Total Offering Amount | $852,525.00 | $125.84 | ||||||||||||
Total Fees Previously Paid | — | |||||||||||||
Total Fee Offsets | — | |||||||||||||
Net Fee Due | $125.84 |
(1) | The number of shares of common stock, par value $0.001 per share (“Common Stock”), of Spero Therapeutics, Inc. (the “Registrant”) stated above consists of additional shares of common stock available for issuance under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (the “2019 Plan”). The maximum number of shares which may be sold upon the exercise of such options or issuance of stock-based awards granted under the 2019 Plan are subject to adjustment in accordance with certain anti-dilution and other provisions of the 2019 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions. |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future grant or issuance under the 2019 Plan are based on the average of the high and the low price of Registrant’s Common Stock as reported on The Nasdaq Global Select Market as of a date (March 11, 2024) within five business days prior to filing this Registration Statement. |